Curative effect of dexrazoxane in patients with breast cancer treated with anthracyclines
LUAN Xiao-dong
GAI Yan-hong
WAN Yue
HOU Hong
MU Qiang
WANG Qi-tang
Abstract：Objective To observe the curative effect of dexrazoxane (DRZ) on cardiotoxicity and its influence on anti-cancer drugs in patients with breast cancer treated with anthracyclines. Methods The patients (n=101) treated with anthracyclines (epirubicin) chemotherapy plan were divided into whole-course DRZ+chemotherapy group (whole-course group with 6 chemotherapy cycles) and half-course DRZ+chemotherapy group (half-course group with later 3 chemotherapy cycles). The changes of electrocardiogram (ECG), sensitive troponin I (TNI), brain natriuretic peptide (BNP), left ventricular end-diastolic volume (LVEDV), and tumor recurrent rate after 1 year were observed and compared between 2 groups. Results The incidence of abnormal ECG and levels of TNI and BNP were lower in whole-course group than those in half-course group after 1 y (P<0.05). LVEDV and tumor recurrent rate after 1 year had no statistical difference between 2 groups (P>0.05). Conclusion The whole-course administration of DRZ has significant preventive effect on cardiotoxicity compared with half-course administration, and DRZ has no significant influence on anti-tumor effect of anthracyclines in patients with breast cancer treated with anthracyclines.
Keywords：DexrazoxaneBreast cancerAnthracyclinesCardiotoxicity
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 482-483,486 )